CD180 and systemic lupus erythematosus: To test this hypothesis, we investigated the treatment effect of anti-CD180 Ab and IgG2b on lupus-symptoms in mice following epicutaneous application of the TLR7 agonist imiquimod (IMQ-mice) according to the treatment schematic shown in Figure 6A.